Skip to main content

InvestorNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Closes on $2.1M Warrant Exercise

SenesTech (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, has closed on its previously announced exercise of certain existing warrants. The transaction comprised the purchase of 2,934,575 shares of SNES common stock at a reduced exercise price per share of $0.7202. SenesTech also issued new warrants to purchase shares of common stock in a private placement; the new warrants are exercisable for up to 5,869,150 shares of common stock at an exercise price of $0.7202 per share. According to the announcement, gross proceeds from the exercise of the existing warrants totaled approximately $2.1 million before placement agent fees and other offering expenses are deducted.

The company plans to use the proceeds from the exercise as working capital and for general corporate purposes, including the rollout of the company’s Isolate Bait System(TM), which is now shipping, and the launch of its new soft-bait product. SNES’s proprietary Isolate Bait product is designed to provide more efficient deployment and incorporates an enhanced formulation of the company’s ContraPest(TM). H.C. Wainwright acted as the exclusive placement agent for the warrant exercise. “In a simple sense, we believe that the proceeds allow us to continue with our plans, which include rolling out the Isolate Bait System as well as launching our new soft-bait product,” said SenesTech president and CEO Joel Fruendt in the press release. “We believe that this financing lets us execute these plans with confidence.”

To view the full press release, visit https://ibn.fm/1ItWz

About SenesTech Inc.

SenesTech are experts at rat-fertility control. The company is passionate about creating a healthy environment by better controlling rat pest populations. SenesTech keeps an inescapable truth in mind: two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. SenesTech invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest-management programs, greatly improving the overall goal of effective rat management. The company strives for clean cities, efficient businesses and happy households by offering a product that was designed to be effective and sustainable without killing rats. SenesTech is committed to improving the health of the world by humanely managing animal populations through fertility control. For more information about the company, please visit www.SenesTech.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.